<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="160692">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01006707</url>
  </required_header>
  <id_info>
    <org_study_id>SU-10212009-4200</org_study_id>
    <nct_id>NCT01006707</nct_id>
  </id_info>
  <brief_title>Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers</brief_title>
  <official_title>fMRI Imaging of Opioid Withdrawal in Healthy Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      Opioid medications are commonly used for pain relief. When given over time, physical
      dependence can occur. This results in unpleasant side effects--such as agitation and
      nausea--if opioid medications are suddenly stopped. However, we do not know how withdrawal
      affects the brain. We know that a medication named Ondansetron can help ease or prevent
      symptoms associated with opioid withdrawal. Through imaging of the brain by fMRI, we hope to
      see how opioid withdrawal, with and without the administration of ondansetron, affects brain
      activity.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fMRI Scan</measure>
    <time_frame>120 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Opioid Withdrawal Scale</measure>
    <time_frame>125 and 135 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Opioid Withdrawal Scale</measure>
    <time_frame>125 and 135 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold Pressor Test</measure>
    <time_frame>125 and 135 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Samples for Genetic Testing</measure>
    <time_frame>125 and 135 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heat Pain Test</measure>
    <time_frame>125 to 135 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Substance-Related Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>In this cross-over study, the blinded patient will receive saline placebo in one session and ondansetron in the other. The order is decided with a randomization table. If ondansetron is randomly chosen, an 8mg IV Bolus will be given at the start of the study for 30 minutes by the unblinded investigator.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients will be healthy male volunteers, ages 18-35.

        Exclusion Criteria

          -  Females were excluded due to menstrual cycle modulation of opioid response.

          -  We will exclude individuals with Raynaud's disease or a history of coronary artery
             disease.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Larry Fu-nien Chu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Compton P, Miotto K, Elashoff D. Precipitated opioid withdrawal across acute physical dependence induction methods. Pharmacol Biochem Behav. 2004 Feb;77(2):263-8.</citation>
    <PMID>14751453</PMID>
  </reference>
  <reference>
    <citation>Compton P, Athanasos P, Elashoff D. Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: a preliminary study. J Pain. 2003 Nov;4(9):511-9.</citation>
    <PMID>14636819</PMID>
  </reference>
  <reference>
    <citation>Stein EA, Pankiewicz J, Harsch HH, Cho JK, Fuller SA, Hoffmann RG, Hawkins M, Rao SM, Bandettini PA, Bloom AS. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am J Psychiatry. 1998 Aug;155(8):1009-15.</citation>
    <PMID>9699686</PMID>
  </reference>
  <reference>
    <citation>Krystal JH, Woods SW, Kosten TR, Rosen MI, Seibyl JP, van Dyck CC, Price LH, Zubal IG, Hoffer PB, Charney DS. Opiate dependence and withdrawal: preliminary assessment using single photon emission computerized tomography (SPECT). Am J Drug Alcohol Abuse. 1995 Feb;21(1):47-63.</citation>
    <PMID>7762544</PMID>
  </reference>
  <reference>
    <citation>Williams TM, Daglish MR, Lingford-Hughes A, Taylor LG, Hammers A, Brooks DJ, Grasby P, Myles JS, Nutt DJ. Brain opioid receptor binding in early abstinence from opioid dependence: positron emission tomography study. Br J Psychiatry. 2007 Jul;191:63-9.</citation>
    <PMID>17602127</PMID>
  </reference>
  <reference>
    <citation>Hui SC, Sevilla EL, Ogle CW. Prevention by the 5-HT3 receptor antagonist, ondansetron, of morphine-dependence and tolerance in the rat. Br J Pharmacol. 1996 Jun;118(4):1044-50.</citation>
    <PMID>8799580</PMID>
  </reference>
  <reference>
    <citation>Pinelli A, Trivulzio S, Tomasoni L. Effects of ondansetron administration on opioid withdrawal syndrome observed in rats. Eur J Pharmacol. 1997 Dec 11;340(2-3):111-9.</citation>
    <PMID>9537805</PMID>
  </reference>
  <reference>
    <citation>Lowe AS, Williams SC, Symms MR, Stolerman IP, Shoaib M. Functional magnetic resonance neuroimaging of drug dependence: naloxone-precipitated morphine withdrawal. Neuroimage. 2002 Oct;17(2):902-10.</citation>
    <PMID>12377164</PMID>
  </reference>
  <verification_date>February 2012</verification_date>
  <lastchanged_date>February 13, 2012</lastchanged_date>
  <firstreceived_date>October 30, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Larry Fu-nien Chu</investigator_full_name>
    <investigator_title>Associate Professor of Anesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
